Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.

Published

Journal Article

We investigated the feasibility of using recombinant human acid-α glucosidase (rhGAA, Alglucosidase alfa), an FDA approved therapy for Pompe disease, as a treatment approach for glycogen storage disease type III (GSD III). An in vitro disease model was established by isolating primary myoblasts from skeletal muscle biopsies of patients with GSD IIIa. We demonstrated that rhGAA significantly reduced glycogen levels in the two GSD IIIa patients' muscle cells (by 17% and 48%, respectively) suggesting that rhGAA could be a novel therapy for GSD III. This conclusion needs to be confirmed in other in vivo models.

Full Text

Duke Authors

Cited Authors

  • Sun, B; Fredrickson, K; Austin, S; Tolun, AA; Thurberg, BL; Kraus, WE; Bali, D; Chen, Y-T; Kishnani, PS

Published Date

  • February 2013

Published In

Volume / Issue

  • 108 / 2

Start / End Page

  • 145 - 147

PubMed ID

  • 23318145

Pubmed Central ID

  • 23318145

Electronic International Standard Serial Number (EISSN)

  • 1096-7206

Digital Object Identifier (DOI)

  • 10.1016/j.ymgme.2012.12.002

Language

  • eng

Conference Location

  • United States